论文部分内容阅读
目的探讨CD40和Id4在子宫内膜癌的表达差异及意义。方法应用免疫组化技术,选取107例子宫内膜癌、50例正常子宫内膜及60例子宫内膜不典型增生,检测CD40和Id4在上述组织中的表达差异。结果 CD40在107例子宫内膜癌中的阳性表达率为68.2%,主要以阳性或强阳性表达为主,阳性表达率显著高于其它两组,差异有统计学意义(P<0.05);CD40在子宫内膜癌高分化、中分化及低分化组的表达分别是29.4%、69.2%、74.5%,其阳性表达率随病理组织学分级的升高而升高,高分化组与其他两组比较,差异有统计学意义(均P<0.05)。Id4在正常子宫内膜、内膜不典型增生、子宫内癌的阳性表达率呈逐渐升高趋势,子宫内腺膜癌组Id4阳性表达率与正常子宫内膜组、子宫内膜不典型组两组间分别比较,差异均有统计学意义(均P<0.05);在子宫内膜癌病理分级中,Id4因子阳性表达率分别为高分化58.8%、中分化66.7%、低分化76.5%,但三组间比较,差异无统计学意义(P>0.05)。结论 CD40、Id4二者的异常表达在子宫内膜癌生物学行为中可能起着重要作用,将来可为子宫内膜癌的生物免疫治疗及基因治疗研究提供新的选择。
Objective To investigate the difference and significance of CD40 and Id4 expression in endometrial carcinoma. Methods The expression of CD40 and Id4 in 107 cases of endometrial carcinoma, 50 cases of normal endometrium and 60 cases of endometrial dysplasia were detected by immunohistochemistry. Results The positive rate of CD40 in 107 cases of endometrial carcinoma was 68.2%, mainly positive or strongly positive, and the positive rate was significantly higher than the other two groups (P <0.05). CD40 In endometrial carcinoma with high differentiated, moderately differentiated and poorly differentiated group, the expression was 29.4%, 69.2%, 74.5%, the positive expression rate increased with the increase of histopathological grade, well-differentiated group and the other two groups The difference was statistically significant (P <0.05). The positive expression rate of Id4 in normal endometrium, endometrial dysplasia and intrauterine cancer showed a gradually increasing trend. The positive rate of Id4 in endometrial cancer group was significantly higher than that in normal endometrial group and endometrial atypical group The difference between the two groups was statistically significant (all P <0.05). In the pathological grade of endometrial carcinoma, the positive rates of Id4 were 58.8%, 66.7%, 76.5% There was no significant difference between the three groups (P> 0.05). Conclusions The abnormal expression of both CD40 and Id4 may play an important role in the biological behavior of endometrial carcinoma. It may provide a new choice for bioimmunotherapy and gene therapy of endometrial carcinoma in the future.